X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Dishman Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs DISHMAN PHARMA - Comparison Results

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA DISHMAN PHARMA AJANTA PHARMA/
DISHMAN PHARMA
 
P/E (TTM) x 24.5 25.1 97.8% View Chart
P/BV x 10.1 3.3 302.3% View Chart
Dividend Yield % 0.6 0.7 89.3%  

Financials

 AJANTA PHARMA   DISHMAN PHARMA
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
DISHMAN PHARMA
Mar-16
AJANTA PHARMA/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,720374 459.4%   
Low Rs1,103129 855.7%   
Sales per share (Unadj.) Rs194.6197.8 98.4%  
Earnings per share (Unadj.) Rs45.221.2 213.2%  
Cash flow per share (Unadj.) Rs50.334.7 144.9%  
Dividends per share (Unadj.) Rs8.002.00 400.0%  
Dividend yield (eoy) %0.60.8 71.3%  
Book value per share (Unadj.) Rs132.0179.9 73.4%  
Shares outstanding (eoy) m88.7780.69 110.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.31.3 570.1%   
Avg P/E ratio x31.211.9 263.0%  
P/CF ratio (eoy) x28.17.2 387.2%  
Price / Book Value ratio x10.71.4 764.2%  
Dividend payout %17.79.4 187.6%   
Avg Mkt Cap Rs m125,29920,306 617.1%   
No. of employees `000NA0.8 0.0%   
Total wages/salary Rs m2,5705,355 48.0%   
Avg. sales/employee Rs ThNM19,252.7-  
Avg. wages/employee Rs ThNM6,459.5-  
Avg. net profit/employee Rs ThNM2,064.1-  
INCOME DATA
Net Sales Rs m17,27515,961 108.2%  
Other income Rs m166265 62.7%   
Total revenues Rs m17,44216,226 107.5%   
Gross profit Rs m5,8074,103 141.5%  
Depreciation Rs m4511,091 41.3%   
Interest Rs m49944 5.2%   
Profit before tax Rs m5,4742,334 234.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,460624 234.1%   
Profit after tax Rs m4,0141,711 234.6%  
Gross profit margin %33.625.7 130.8%  
Effective tax rate %26.726.7 99.8%   
Net profit margin %23.210.7 216.7%  
BALANCE SHEET DATA
Current assets Rs m7,63911,018 69.3%   
Current liabilities Rs m2,7159,517 28.5%   
Net working cap to sales %28.59.4 303.1%  
Current ratio x2.81.2 243.1%  
Inventory Days Days43110 39.1%  
Debtors Days Days7935 225.8%  
Net fixed assets Rs m6,91416,304 42.4%   
Share capital Rs m177161 109.6%   
"Free" reserves Rs m11,44212,907 88.6%   
Net worth Rs m11,72114,516 80.7%   
Long term debt Rs m1494,189 3.5%   
Total assets Rs m14,81429,805 49.7%  
Interest coverage x112.93.5 3,253.9%   
Debt to equity ratio x00.3 4.4%  
Sales to assets ratio x1.20.5 217.8%   
Return on assets %27.48.9 307.8%  
Return on equity %34.211.8 290.5%  
Return on capital %46.517.5 265.4%  
Exports to sales %55.124.8 222.5%   
Imports to sales %6.03.7 160.8%   
Exports (fob) Rs m9,5273,956 240.8%   
Imports (cif) Rs m1,038596 174.0%   
Fx inflow Rs m10,4224,952 210.5%   
Fx outflow Rs m1,678697 240.8%   
Net fx Rs m8,7444,255 205.5%   
CASH FLOW
From Operations Rs m3,2642,786 117.1%  
From Investments Rs m-2,093-1,529 136.9%  
From Financial Activity Rs m-1,186-941 126.0%  
Net Cashflow Rs m-15316 -4.7%  

Share Holding

Indian Promoters % 73.8 61.4 120.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 3.7 41.9%  
FIIs % 7.6 12.7 59.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 22.1 76.9%  
Shareholders   20,968 46,261 45.3%  
Pledged promoter(s) holding % 4.4 35.8 12.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   SANOFI INDIA  TORRENT PHARMA  PLETHICO PHARMA  CIPLA  ABBOTT INDIA  

Compare AJANTA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Weak Start to the Week; PSU & Metal Stocks Fall(Closing)

Indian share markets continued to witness selling pressure in the afternoon session as benchmark Sensex slipped below the 34,000-mark.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Feb 19, 2018 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 5-YR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS